Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
3.020
+0.030 (1.00%)
At close: Mar 16, 2026, 4:00 PM EDT
3.000
-0.020 (-0.66%)
After-hours: Mar 16, 2026, 7:03 PM EDT
Imunon Employees
Imunon had 25 employees as of December 31, 2024. The number of employees decreased by 8 or -24.24% compared to the previous year.
Employees
25
Change (1Y)
-8
Growth (1Y)
-24.24%
Revenue / Employee
n/a
Profits / Employee
-$573,176
Market Cap
9.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 25 | -8 | -24.24% |
| Dec 31, 2023 | 33 | 2 | 6.45% |
| Dec 31, 2022 | 31 | 2 | 6.90% |
| Dec 31, 2021 | 29 | 2 | 7.41% |
| Dec 31, 2020 | 27 | -2 | -6.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| Theriva Biologics | 22 |
| BiomX | 20 |
| SeaStar Medical Holding | 19 |
| Quantum BioPharma | 17 |
| Cardio Diagnostics Holdings | 15 |
| Iterum Therapeutics | 9 |
| Akari Therapeutics, | 9 |
IMNN News
- 5 weeks ago - IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY - GlobeNewsWire
- 2 months ago - IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 2 months ago - IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 - GlobeNewsWire
- 4 months ago - Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript - Seeking Alpha
- 4 months ago - IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer - GlobeNewsWire
- 4 months ago - IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer - GlobeNewsWire